HUTCHMED (China) Limited (NASDAQ:HCM) Shares Acquired by Summit Trail Advisors LLC

Summit Trail Advisors LLC increased its position in shares of HUTCHMED (China) Limited (NASDAQ:HCM) by 14.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,090 shares of the company’s stock after acquiring an additional 1,647 shares during the period. Summit Trail Advisors LLC’s holdings in HUTCHMED were worth $189,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of HCM. M&G PLC lifted its stake in HUTCHMED by 98.1% during the 3rd quarter. M&G PLC now owns 267,231 shares of the company’s stock worth $5,345,000 after acquiring an additional 132,333 shares in the last quarter. Jane Street Group LLC lifted its stake in HUTCHMED by 362.2% during the 3rd quarter. Jane Street Group LLC now owns 62,997 shares of the company’s stock worth $1,305,000 after acquiring an additional 49,366 shares in the last quarter. XY Capital Ltd acquired a new position in HUTCHMED during the 4th quarter worth about $673,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in HUTCHMED by 99.0% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 48,724 shares of the company’s stock worth $952,000 after purchasing an additional 24,245 shares during the period. Finally, Point72 Hong Kong Ltd purchased a new stake in HUTCHMED during the 3rd quarter worth about $421,000. Institutional investors and hedge funds own 8.82% of the company’s stock.

HUTCHMED Trading Up 1.0 %

Shares of NASDAQ HCM opened at $13.22 on Friday. The stock’s 50-day moving average is $14.54 and its two-hundred day moving average is $17.07. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.68 and a current ratio of 2.81. HUTCHMED has a 1-year low of $12.84 and a 1-year high of $21.92.

Analyst Ratings Changes

Separately, StockNews.com downgraded HUTCHMED from a “buy” rating to a “hold” rating in a report on Monday, November 18th.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.